# Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

> **NCT04084951** · PHASE1 · COMPLETED · sponsor: **SQZ Biotechnologies** · enrollment: 30 (actual)

## Conditions studied

- Adult Solid Tumor

## Interventions

- **BIOLOGICAL:** SQZ-PBMC-HPV
- **DRUG:** Atezolizumab
- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04084951
- **Lead sponsor:** SQZ Biotechnologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-28
- **Primary completion:** 2023-02-09
- **Final completion:** 2023-02-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04084951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04084951, "Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT04084951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*